A Study of LY3985863 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-11

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First-In-Human Study of LY3985297 in Healthy Participants

NCT06395012

Healthy

COMPLETED PHASE1

A Study of LY3848575 in Healthy Participants

NCT05727072

Healthy

COMPLETED PHASE1

A Study of LY3867070 in Healthy Participants

NCT07021547

Healthy

RECRUITING PHASE1

A Study of LY3981314 in Healthy Participants

NCT07005284

Healthy

RECRUITING PHASE1

A Study of LY3041658 in Healthy Participants

NCT04653168

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3985863

Administered subcutaneously (SC)

Group Type EXPERIMENTAL

LY3985863

Intervention Type DRUG

Administered SC

Placebo

Administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3985863

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are native Chinese participants
* Are overtly healthy
* Have body weight of at least 50.0 kilogram (kg) for male or 45.0 kg for female and a body mass index of 20.0 to 30.0 kilogram per square meter (kg/m²), inclusive
* Have a stable body weight within 3 months

Exclusion Criteria

* Have known allergies to any components of the LY3985863 formulation
* Have concomitant disease known to influence skeletal muscle protein
* Have current or a history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study medication or completing study procedures, or of interfering with the interpretation of the data
* Have a 12-lead echocardiogram (ECG) abnormality
* Have used within 3 months or intend to use medications during the study that promote weight loss

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes